Douillard J Y, Chatal J F
Centre René-Gauducheau, Site hospitalier Nord de Nantes-Saint-Herblain.
Bull Cancer. 1998 Nov;85(11):951-9.
During the last 15 years, various antibodies specific for antigens associated with determined types of cancer have been used therapeutically, including some in unlabeled forms as immune effectors. The results of clinical studies have been unpromising for patients with colorectal cancer at the advanced metastatic stage but much more favorable in terms of increased survival for the adjuvant situation of residual microscopic disease. Antibodies have also been used as carriers for cytotoxic substances, but with rather disappointing clinical results when they were labeled with toxins or antimitotic agents. The results have been variable for labeling with radionuclides (mainly iodine-131), some-times proving quite favorable for refractory forms of non-hodgkin's lymphomas or acute leukemias. In this last indication, radioimmunotherapy has been associated with chemotherapy to enhance action before a bone-marrow graft. However, the clinical results have been disappointing in the treatment of solid tumors, showing responses only in the case of small targets. In the future, treatment with antibodies will focus on microscopic tumors, in association with other therapeutic modalities especially, chemotherapy and biotherapy.
在过去15年中，针对与特定类型癌症相关抗原的各种特异性抗体已被用于治疗，包括一些未标记形式作为免疫效应物。临床研究结果对于晚期转移性结直肠癌患者并不乐观，但对于残留微小病灶的辅助治疗情况，在提高生存率方面则更为有利。抗体也被用作细胞毒性物质的载体，但当它们与毒素或抗有丝分裂剂结合时，临床结果相当令人失望。用放射性核素（主要是碘-131）标记的结果各不相同，有时对难治性非霍奇金淋巴瘤或急性白血病形式相当有利。在这最后一种适应症中，放射免疫疗法已与化疗联合使用，以在骨髓移植前增强疗效。然而，在实体瘤治疗中，临床结果令人失望，仅在小靶点情况下显示出反应。未来，抗体治疗将集中于微小肿瘤，并与其他治疗方式特别是化疗和生物疗法联合使用。
